Gain Therapeutics, Inc.
GANX· Nasdaq
Released Aug 11, 2026, after the close
10-Q filed Aug 11, 2026, 42 days after period end · 0001104659-26-094048
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | — | — | — | $0.00 |
| Net Income | -$4.68M | -$5.81M | -$8.14M | -$7.69M |
| EPS Diluted |
Gain Therapeutics, Inc. · CIK 1819411 · Engraved from SEC EDGAR
| -$0.11 |
| -$0.19 |
| -$0.42 |
| -$0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.